Cytomegalovirus News and Research

RSS

Cytomegalovirus (CMV) is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella-zoster virus (which causes chickenpox), and Epstein-Barr virus (which causes infectious mononucleosis). Infection with CMV is a major cause of disease and death in immunocompromised patients, including organ transplant recipients, patients undergoing hemodialysis, patients with cancer, patients receiving immunosuppressive drugs, and HIV-infected patients. While drugs are available for treatment of these conditions, the primary drug choices carry significant side effects and warnings. Currently, there are no anti-CMV drugs indicated for treatment of primary CMV infection during pregnancy resulting in infections that can have catastrophic consequences to the newborn. Maternal-fetal transfer of CMV infection results in a fetal death rate of 12% and most survivors have permanent debilitating disorders, including mental retardation, vision loss, and sensorineural deafness.

Viruses and genes may increase risk of schizophrenia

Viruses and genes interact in a way that may increase the risk of developing schizophrenia significantly. This happens already in the developing foetus.

11 Mar 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

New study: Loneliness can harm overall health

New research links loneliness to a number of dysfunctional immune responses, suggesting that being lonely has the potential to harm overall health.

20 Jan 2013

Stem cells give insight into path of cytomegalovirus infection

Primitive human stem cells are resistant to human cytomegalovirus, say researchers who believe this finding could provide further insight into disease pathology.

3 Dec 2012

Primitive human stem cells resistant to human cytomegalovirus

A new study published online in PLOS ONE reveals that primitive human stem cells are resistant to human cytomegalovirus (HCMV), one of the leading prenatal causes of congenital intellectual disability, deafness and deformities worldwide.

30 Nov 2012

Max Planck scientists identify unknown proteins of the herpesvirus

The genome encodes the complete information needed by an organism, including that required for protein production. Viruses, which are up to a thousand times smaller than human cells, have considerably smaller genomes. Using a type of herpesvirus as a model system, the scientists of the Max Planck Institute of Biochemistry in Martinsried near Munich and their collaboration partners at the University of California in San Francisco have shown that the genome of this virus contains much more information than previously assumed.

26 Nov 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Research reveals surprisingly complex protein-coding capacity of human cytomegalovirus

New findings reveal the surprisingly complex protein-coding capacity of the human cytomegalovirus, or HCMV, and provide the first steps toward understanding how the virus manipulates human cells during infection. The genome of the HCMV was first sequenced over 20 years ago, but researchers have now investigated the proteome-the complete set of expressed proteins-of this common pathogen as well.

23 Nov 2012

Scientists solve mystery behind what triggers the herpes virus to become active again

The mere mention of the word "herpes" usually conjures negative images and stereotypes, but most people have been infected with some form of the virus. For most, a sore appears, heals and is forgotten, although the virus remains latent just waiting for the right circumstances to come back. Now, the mystery behind what triggers the virus to become active again is closer to being solved thanks to new research published in the Journal of Leukocyte Biology's November 2012 issue.

1 Nov 2012

Merck, AiCuris enter licensing agreement for novel HCMV candidates

Merck, known as MSD outside the United States and Canada, and AiCuris today announced that they have entered into an exclusive worldwide licensing agreement for AiCuris' novel portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of HCMV infection in transplant recipients.

15 Oct 2012

Trellis, OMT enter collaboration to generate human antibodies

Trellis Bioscience LLC and Open Monoclonal Technology, Inc. today announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT's OmniRat platform.

8 Oct 2012

New test to assess viral load of cytomegalovirus

Roche announced today the commercial availability of a new test to assess a patient's viral load of cytomegalovirus (CMV). Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically patients with an immune system that has been suppressed for solid organ transplantation.

From Roche Sequencing and Life Science 17 Sep 2012

Smoking history 'no bar to successful lung donation'

Although lung transplantation from donors with a positive smoking history is associated with worse outcomes than with lungs from non-smoking donors, survival is still better than remaining on the waiting list, say UK researchers.

13 Sep 2012

Herpes virus eventually impairs glucose regulation

The common herpes virus cytomegalovirus may be a risk factor for the development of Type 2 diabetes among elderly individuals, show study findings.

3 Sep 2012

Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients

Waiting to treat the commonest viral infections in transplant recipients until they reach a certain threshold is better than prophylactically treating all recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

24 Aug 2012

Vanderbilt researchers receives new $2.1M grant to develop microbrain bioreactor

Take a millionth of a human brain and squeeze it into a special chamber the size of a mustard seed. Link it to a second chamber filled with cerebral spinal fluid and thread both of them with artificial blood vessels in order to create a microenvironment that makes the neurons and other brain cells behave as if they were in a living brain. Then surround the chambers with a battery of sensors that monitor how the cells respond when exposed to minute quantities of dietary toxins, disease organisms or new drugs under development.

25 Jul 2012

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.

24 Jul 2012

T. gondii link to schizophrenia supported

Study results support an associated between maternal infection with Toxoplasma gondii and an increased risk for schizophrenia in offspring.

24 Jul 2012

Specific therapy may cut pneumonia mortality in HIV babies

The high mortality rate associated with acute severe pneumonia-related respiratory failure in infants exposed to or infected with HIV can be reduced to 30% if a treatment plan involving antibiotics, ventilation, and fluid restriction is used, researchers report.

17 Jul 2012

Roche receives FDA approval for CMV viral load test

The U.S. Food and Drug Administration today approved the first DNA test to help health care professionals gauge the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy.

6 Jul 2012